Drug intelligence / Profile preview

GSK2838500A

Development stage: Preclinical
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK2838500A is an investigational vaccine candidate developed by GSK (GlaxoSmithKline) Biologicals targeting non-typeable Haemophilus influenzae (NTHi). NTHi is a significant cause of respiratory tract infections, particularly in children and individuals with chronic lung diseases. The vaccine contains antigens derived from NTHi and is designed to elicit an immune response against this pathogen, potentially reducing the incidence or severity of related infections[1][2]. The primary developer and sponsor for clinical studies involving this candidate is GSK Biologicals.

Beyond the preview

Go deeper on GSK2838500A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2838500A.

Explore the full profile